Baader Bank Aktiengesellschaft Purchases New Holdings in BridgeBio Pharma, Inc. $BBIO

Baader Bank Aktiengesellschaft purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,525 shares of the company’s stock, valued at approximately $650,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of BridgeBio Pharma during the 2nd quarter valued at $25,000. Jones Financial Companies Lllp bought a new stake in BridgeBio Pharma during the first quarter worth about $35,000. First Horizon Corp acquired a new stake in BridgeBio Pharma during the third quarter worth about $36,000. AlphaQuest LLC increased its holdings in BridgeBio Pharma by 254.3% in the 3rd quarter. AlphaQuest LLC now owns 815 shares of the company’s stock valued at $42,000 after buying an additional 585 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of BridgeBio Pharma by 28.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock valued at $53,000 after buying an additional 227 shares in the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at BridgeBio Pharma

In other news, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $74.26, for a total transaction of $148,520.00. Following the completion of the transaction, the chief accounting officer owned 130,297 shares of the company’s stock, valued at approximately $9,675,855.22. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Andrew Lo sold 55,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $65.69, for a total transaction of $3,612,950.00. Following the transaction, the director owned 50,583 shares in the company, valued at approximately $3,322,797.27. This trade represents a 52.09% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 260,700 shares of company stock worth $18,157,071 over the last quarter. Insiders own 18.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Morgan Stanley started coverage on shares of BridgeBio Pharma in a research report on Tuesday, January 6th. They set an “overweight” rating and a $96.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Wednesday, January 21st. Sanford C. Bernstein initiated coverage on BridgeBio Pharma in a report on Thursday, December 11th. They set an “outperform” rating and a $94.00 price target for the company. TD Cowen restated a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, January 12th. Finally, Leerink Partners lifted their target price on BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Twenty-two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $79.05.

BridgeBio Pharma Trading Up 1.2%

BridgeBio Pharma stock opened at $73.33 on Thursday. The stock has a 50-day moving average price of $75.54 and a two-hundred day moving average price of $62.79. BridgeBio Pharma, Inc. has a 12 month low of $28.33 and a 12 month high of $81.32. The company has a market capitalization of $14.13 billion, a PE ratio of -17.54 and a beta of 1.13.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.